Cervical Cancer
Selected Stage III cervical cancer patients treated by high-dose-rate brachytherapy
Published in Clinical Oncology Week, November 6th, 2006
"The use of brachytherapy in the treatment of cervical cancer has increased worldwide since its initial introduction over 100 years ago. However, certain aspects of the use of HDR versus low-dose-rate (LDR) brachytherapy continue to be controversial, particularly the role of HDR in FIGO Stage III cervical cancer and the use of HDR with concurrent chemotherapy," scientists in the United States reported.
"This study represents a systematic literature...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Gastrinoma
Zollinger-Ellison syndrome patients should undergo routine surgical exploration - Leukemia
Myelodysplastic syndrome patients benefited from azacitidine - Melanoma
Melanoma screenings should be conducted in first-degree relatives of recently diagnosed patients - Clinical Trials
Studies from Massachusetts General Hospital, Department of Radiation Oncology yield new information about clinical trials - Drug Discovery
Research from Bristol-Myers Squibb Company, Inc. yields new data on drug discovery - Granuloma Prevention
Studies from University of Amsterdam, Department of Oral and Maxillofacial Surgery update current data on granuloma prevention - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
